$1.63 Billion is the total value of Eventide Asset Management's 129 reported holdings in Q2 2016. The portfolio turnover from Q1 2016 to Q2 2016 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CELG | CELGENE CORP | $69,278,000 | -1.5% | 702,400 | 0.0% | 4.24% | +7.9% | |
| LEA | LEAR CORP | $44,673,000 | -8.5% | 439,000 | 0.0% | 2.73% | +0.3% | |
| XPO | XPO LOGISTICS INC | $42,497,000 | -14.5% | 1,618,300 | 0.0% | 2.60% | -6.3% | |
| MBBYF | MOBILEYE N V AMSTELVEEN | $40,317,000 | +23.7% | 873,800 | 0.0% | 2.47% | +35.5% | |
| SPLK | SPLUNK INC | $35,661,000 | +10.7% | 658,200 | 0.0% | 2.18% | +21.2% | |
| CYBR | CYBERARK SOFTWARE LTD | $34,013,000 | +14.0% | 700,000 | 0.0% | 2.08% | +24.8% | |
| SGEN | SEATTLE GENETICS INC | $33,763,000 | +15.2% | 835,506 | 0.0% | 2.07% | +26.1% | |
| PFPT | PROOFPOINT INC | $31,097,000 | +17.3% | 492,900 | 0.0% | 1.90% | +28.5% | |
| ASML | ASML Holding NV | $31,023,000 | -1.2% | 312,700 | 0.0% | 1.90% | +8.2% | |
| ATHN | ATHENAHEALTH INC | $27,768,000 | -0.6% | 201,200 | 0.0% | 1.70% | +8.9% | |
| IPHI | INPHI CORP | $25,595,000 | -3.9% | 799,100 | 0.0% | 1.57% | +5.2% | |
| WAB | WABTEC CORP | $24,581,000 | -11.4% | 350,000 | 0.0% | 1.50% | -3.0% | |
| WBC | WABCO HLDGS INC | $23,405,000 | -14.4% | 255,600 | 0.0% | 1.43% | -6.2% | |
| BLUE | BLUEBIRD BIO INC | $23,355,000 | +1.9% | 539,500 | 0.0% | 1.43% | +11.6% | |
| IDTI | INTEGRATED DEVICE TECHNOLOGY | $21,070,000 | -1.5% | 1,046,700 | 0.0% | 1.29% | +7.9% | |
| SYNA | SYNAPTICS INC | $20,989,000 | -32.6% | 390,500 | 0.0% | 1.28% | -26.2% | |
| MGNX | MACROGENICS INC | $19,589,000 | +43.9% | 725,800 | 0.0% | 1.20% | +57.8% | |
| CRUS | CIRRUS LOGIC INC | $19,395,000 | +6.5% | 500,000 | 0.0% | 1.19% | +16.7% | |
| LOXO | LOXO ONCOLOGY INC | $17,153,000 | -15.2% | 740,000 | 0.0% | 1.05% | -7.1% | |
| CBI | CHICAGO BRIDGE & IRON CO N V | $16,913,000 | -5.4% | 488,400 | 0.0% | 1.04% | +3.6% | |
| STKL | SUNOPTA INC | $16,059,000 | -6.0% | 3,832,600 | 0.0% | 0.98% | +2.9% | |
| NVAX | NOVAVAX INC | $15,846,000 | +40.9% | 2,179,700 | 0.0% | 0.97% | +54.5% | |
| SPWR | SUNPOWER CORP | $15,490,000 | -30.7% | 1,000,000 | 0.0% | 0.95% | -24.0% | |
| LLTC | LINEAR TECHNOLOGY CORP | $13,615,000 | +4.4% | 292,600 | 0.0% | 0.83% | +14.3% | |
| AGIO | AGIOS PHARMACEUTICALS INC | $12,602,000 | +3.2% | 300,800 | 0.0% | 0.77% | +13.0% | |
| SUPN | SUPERNUS PHARMACEUTICALS INC | $11,713,000 | +33.6% | 575,000 | 0.0% | 0.72% | +46.3% | |
| VCYT | VERACYTE INC | $11,328,000 | -6.8% | 2,252,000 | 0.0% | 0.69% | +1.9% | |
| ACAD | ACADIA PHARMACEUTICALS INC | $10,864,000 | +16.1% | 334,700 | 0.0% | 0.66% | +27.2% | |
| CSIQ | CANADIAN SOLAR INC | $9,072,000 | -21.6% | 600,000 | 0.0% | 0.56% | -14.1% | |
| AYR | AIRCASTLE LTD | $8,383,000 | -12.1% | 428,600 | 0.0% | 0.51% | -3.8% | |
| DBVT | DBV TECHNOLOGIES S Asponsored adr | $8,142,000 | +0.2% | 249,600 | 0.0% | 0.50% | +9.7% | |
| ONCE | SPARK THERAPEUTICS INC | $7,670,000 | +73.3% | 150,000 | 0.0% | 0.47% | +89.9% | |
| KITE | KITE PHARMA INC | $7,430,000 | +8.9% | 148,600 | 0.0% | 0.46% | +19.4% | |
| ESSA PHARMA INC | $7,370,000 | -5.8% | 2,719,410 | 0.0% | 0.45% | +3.2% | ||
| CSLT | CASTLIGHT HEALTH INCcl b | $6,766,000 | +18.9% | 1,708,600 | 0.0% | 0.41% | +30.2% | |
| GWPH | GW PHARMACEUTICALS PLCads | $6,730,000 | +26.9% | 73,500 | 0.0% | 0.41% | +39.2% | |
| XNCR | XENCOR INC | $6,533,000 | +41.5% | 344,000 | 0.0% | 0.40% | +55.0% | |
| CERN | CERNER CORP | $6,341,000 | +10.7% | 108,200 | 0.0% | 0.39% | +21.2% | |
| BMRN | BIOMARIN PHARMACEUTICAL INC | $5,835,000 | -5.7% | 75,000 | 0.0% | 0.36% | +3.2% | |
| STML | STEMLINE THERAPEUTICS INC | $5,764,000 | +45.3% | 851,400 | 0.0% | 0.35% | +59.0% | |
| NBIX | NEUROCRINE BIOSCIENCES INC | $5,681,000 | +14.9% | 125,000 | 0.0% | 0.35% | +26.1% | |
| MCRB | SERES THERAPEUTICS INC | $5,177,000 | +9.4% | 178,200 | 0.0% | 0.32% | +20.1% | |
| SAGE | SAGE THERAPEUTICS INC | $5,122,000 | -6.0% | 170,000 | 0.0% | 0.31% | +2.6% | |
| ALNY | ALNYLAM PHARMACEUTICALS INC | $4,994,000 | -11.6% | 90,000 | 0.0% | 0.31% | -3.2% | |
| RARE | ULTRAGENYX PHARMACEUTICAL IN | $4,275,000 | -22.7% | 87,400 | 0.0% | 0.26% | -15.2% | |
| PRTA | PROTHENA CORP PLC | $4,195,000 | -15.1% | 120,000 | 0.0% | 0.26% | -6.9% | |
| AGTC | APPLIED GENETIC TECHNOL CORP | $3,944,000 | +1.1% | 279,100 | 0.0% | 0.24% | +10.6% | |
| DVAX | DYNAVAX TECHNOLOGIES CORP | $3,645,000 | -24.2% | 250,000 | 0.0% | 0.22% | -17.1% | |
| JUNO | JUNO THERAPEUTICS INC | $3,460,000 | +0.9% | 90,000 | 0.0% | 0.21% | +10.4% | |
| VYGR | VOYAGER THERAPEUTICS INC | $3,297,000 | +25.9% | 300,000 | 0.0% | 0.20% | +38.4% | |
| TGTX | TG THERAPEUTICS INC | $3,258,000 | -28.9% | 537,600 | 0.0% | 0.20% | -22.3% | |
| INCY | INCYTE CORP | $3,199,000 | +10.3% | 40,000 | 0.0% | 0.20% | +21.0% | |
| CEMP | CEMPRA INC | $3,049,000 | -5.9% | 184,900 | 0.0% | 0.19% | +3.3% | |
| RGEN | REPLIGEN CORP | $3,010,000 | +2.0% | 110,000 | 0.0% | 0.18% | +11.5% | |
| VRTX | VERTEX PHARMACEUTICALS INC | $2,976,000 | +8.2% | 34,600 | 0.0% | 0.18% | +18.2% | |
| GLPG | GALAPAGOS NVspon adr | $2,884,000 | +32.6% | 52,000 | 0.0% | 0.18% | +44.3% | |
| NTUS | NATUS MEDICAL INC DEL | $2,835,000 | -1.6% | 75,000 | 0.0% | 0.17% | +7.5% | |
| EPZM | EPIZYME INC | $2,816,000 | -15.5% | 275,000 | 0.0% | 0.17% | -7.5% | |
| CDTX | CIDARA THERAPEUTICS INC | $2,722,000 | -18.8% | 264,000 | 0.0% | 0.17% | -10.7% | |
| GBT | GLOBAL BLOOD THERAPEUTICS IN | $2,737,000 | +4.6% | 165,000 | 0.0% | 0.17% | +14.4% | |
| ATRC | ATRICURE INC | $2,543,000 | -16.0% | 180,000 | 0.0% | 0.16% | -7.7% | |
| CHRS | COHERUS BIOSCIENCES INC | $2,449,000 | -20.4% | 145,000 | 0.0% | 0.15% | -12.8% | |
| PTI | PROTEOSTASIS THERAPEUTICS IN | $2,426,000 | +25.8% | 200,000 | 0.0% | 0.15% | +37.0% | |
| OMED | ONCOMED PHARMACEUTICALS INC | $2,339,000 | +21.8% | 190,000 | 0.0% | 0.14% | +33.6% | |
| TCON | TRACON PHARMACEUTICALS INC | $2,268,000 | -37.3% | 517,700 | 0.0% | 0.14% | -31.2% | |
| CTMX | CYTOMX THERAPEUTICS INC | $1,532,000 | -20.8% | 150,000 | 0.0% | 0.09% | -13.0% | |
| IMDZ | IMMUNE DESIGN CORP | $1,469,000 | -37.2% | 180,000 | 0.0% | 0.09% | -31.3% | |
| ZSAN | ZOSANO PHARMA CORP | $1,173,000 | -42.6% | 888,300 | 0.0% | 0.07% | -36.8% | |
| DRNA | DICERNA PHARMACEUTICALS INC | $1,131,000 | -44.0% | 377,000 | 0.0% | 0.07% | -38.9% | |
| WELL | WELLTOWER INC | $274,000 | +9.6% | 3,600 | 0.0% | 0.02% | +21.4% | |
| VTR | VENTAS INC | $124,000 | +15.9% | 1,700 | 0.0% | 0.01% | +33.3% | |
| TESLA MTRS INCnote 0.250% 3/0 | $89,000 | -2.2% | 100,000 | 0.0% | 0.01% | 0.0% | ||
| NATI | NATIONAL INSTRS CORP | $77,000 | -8.3% | 2,800 | 0.0% | 0.01% | 0.0% | |
| TERP | TERRAFORM PWR INC | $51,000 | +27.5% | 4,650 | 0.0% | 0.00% | +50.0% | |
| GLBL | TERRAFORM GLOBAL INCcl a | $28,000 | +33.3% | 8,700 | 0.0% | 0.00% | +100.0% | |
| RMR | RMR GROUP INCcl a | $1,000 | 0.0% | 37 | 0.0% | 0.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-08-15
About Eventide Asset Management
Eventide Asset Management is a Boston-based investment firm that specializes in providing investment solutions to investors who are looking for long-term growth opportunities. The company was founded in 2008 by a group of experienced investment professionals who shared a common vision of creating a firm that would focus on investing in companies that are making a positive impact on society.
The company's investment philosophy is based on the belief that companies that are making a positive impact on society are more likely to be successful in the long run. Eventide's investment team conducts extensive research to identify companies that are aligned with this philosophy and have the potential to deliver strong returns over the long term.
The company's investment strategies are managed by a team of experienced professionals, including CEO Robin John, COO Finny Kuruvilla, and Chief Investment Officer, Dr. Finny Kuruvilla. The team has a proven track record of delivering strong returns to investors, and their investment strategies have been recognized by industry experts.
Eventide Asset Management offers a range of investment solutions, including mutual funds, separately managed accounts, and exchange-traded funds (ETFs). The company's funds are available to individual investors, financial advisors, and institutional investors.
Overall, Eventide Asset Management is a reputable investment firm that has a strong focus on investing in companies that are making a positive impact on society. The company's experienced investment team and proven track record make it a compelling option for investors who are looking for long-term growth opportunities.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| LOWES COS INC | 40 | Q3 2023 | 3.2% |
| PALO ALTO NETWORKS INC | 40 | Q3 2023 | 3.6% |
| ASML HOLDINGS NV | 40 | Q3 2023 | 1.9% |
| NEUROCRINE BIOSCIENCES INC | 40 | Q3 2023 | 1.1% |
| REPLIGEN CORP | 40 | Q3 2023 | 0.5% |
| VERACYTE INC | 38 | Q3 2023 | 1.5% |
| LAM RESEARCH CORP | 35 | Q3 2023 | 3.4% |
| XPO LOGISTICS INC | 34 | Q1 2023 | 3.8% |
| COLLEGIUM PHARMACEUTICAL INC | 34 | Q3 2023 | 2.6% |
| MAGNA INTL INC | 33 | Q4 2021 | 2.5% |
View Eventide Asset Management's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cogent Biosciences, Inc. | February 14, 2023 | 2,589,778 | 3.7% |
| ESSA Pharma Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Freeline Therapeutics Holdings plc | February 14, 2023 | 5,920,765 | 9.1% |
| KnowBe4, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Praxis Precision Medicines, Inc. | February 14, 2023 | 3,518,062 | 7.5% |
| Prometheus Biosciences, Inc. | February 14, 2023 | 1,032,938 | 2.2% |
| SUTRO BIOPHARMA, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| Vital Farms, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Zymeworks Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Entasis Therapeutics Holdings Inc. | February 14, 2022 | 590,602 | 1.2% |
View Eventide Asset Management's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-02-20 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Eventide Asset Management's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.